Forty‐eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas

Autor: Xieda Zhou, Xiaopei Cao, Xiaoyu Huang, Liting Wu, Yan Chen, Yanbing Li, Haipeng Xiao, Huangmeng Xiao
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Endocrinology
Diabetes and Metabolism
Atorvastatin
medicine.medical_treatment
030204 cardiovascular system & hematology
Gastroenterology
chemistry.chemical_compound
0302 clinical medicine
High‐density lipoprotein cholesterol
030212 general & internal medicine
Femur
General Medicine
Articles
Middle Aged
Lipids
Plaque
Atherosclerotic
Clinical Science and Care
Treatment Outcome
Lower Extremity
Quinolines
lipids (amino acids
peptides
and proteins)
Original Article
Female
medicine.drug
medicine.medical_specialty
Statin
medicine.drug_class
Carbohydrate metabolism
Diseases of the endocrine glands. Clinical endocrinology
Drug Administration Schedule
03 medical and health sciences
Diabetes mellitus
Internal medicine
Internal Medicine
medicine
Humans
Pitavastatin
Aged
Triglyceride
business.industry
Statins
Type 2 Diabetes Mellitus
nutritional and metabolic diseases
Cholesterol
LDL
RC648-665
medicine.disease
Lower extremity atherosclerotic disease
Atherosclerosis
chemistry
Amputation
Diabetes Mellitus
Type 2
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Zdroj: Journal of Diabetes Investigation
Journal of Diabetes Investigation, Vol 12, Iss 7, Pp 1278-1286 (2021)
ISSN: 2040-1124
2040-1116
Popis: Aims/Introduction Type 2 diabetes mellitus is correlated with systemic atherosclerosis. Statin therapies have been proved to reduce low‐density lipoprotein cholesterol (LDL‐C) level, protecting type 2 diabetes mellitus patients from cardiovascular events. Recently, more interest has been focused on the regression of lower extremity atherosclerotic disease (LEAD) for the potential prevention of amputation. However, the effects of pitavastatin and atorvastatin on LEAD in type 2 diabetes mellitus patients have not been directly compared. Materials and Methods This study compared the effects of pitavastatin and atorvastatin on femoral total plaque areas (FTPA), and lipids and glucose metabolism in type 2 diabetes mellitus patients with elevated LDL‐C level and LEAD. Type 2 diabetes mellitus patients with LDL‐C level >2.6 mmol/L and LEAD were randomly assigned to receive either pitavastatin 2 mg/day or atorvastatin 10 mg/day for 48 weeks. FTPA were measured at baseline and the end of the study. Levels of glucose and lipids profile were measured periodically. The efficacy was evaluated in 63 patients. Results The percentage change in FTPA measurements was similar between the pitavastatin group and atorvastatin group (−17.79 ± 21.27% vs −14.34 ± 16.33%), as were the changes in LDL‐C (−44.0 ± 18.0% vs −40.3 ± 18.2%) and triglyceride (17.6 ± 20.0% vs 16.2 ± 17.0%). However, the level of high‐density lipoprotein cholesterol was significantly higher in the pitavastatin group compared with the atorvastatin group after 48 weeks of treatment (12.9 ± 10.3% vs 7.2 ± 11.7%, P
Forty‐eight weeks of treatment with either pitavastatin or atorvastatin was associated with significant regression of femoral total plaque areas. However, pitavastatin treatment resulted in a significantly higher high‐density lipoprotein cholesterol level compared with atorvastatin treatment. It seemed that pitavastatin might be superior in the control of dyslipidemia in diabetes patients.
Databáze: OpenAIRE
Externí odkaz: